Navigation Links
Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
Date:2/4/2009

CPF Calls on Manufacturer and FDA to Expedite Review of Pirfenidone as Treatment for PF

SAN JOSE, Calif., Feb. 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is calling this a historic time in the research and treatment of PF, as a pivotal Phase III clinical trial is completed for Pirfenidone and data released. The positive data could pave the way for the first FDA-approved therapy to treat PF - a relentlessly progressive and ultimately fatal lung disease affecting more than 128,000 people and claiming 40,000 lives each year. The CPF urges the FDA to review this study as soon as possible, given that there are no current FDA-approved treatments for PF.

"For patients living with a lethal and ultimately fatal disease, these data indicate that Pirfenidone may allow them breathe better, walk further, and live longer," said CPF Founder and Chief Operating Officer Mark Shreve. "If approved, Pirfenidone would represent a historic and desperately needed advance in the treatment of PF."

This milestone in research for PF treatments takes on particular meaning for the CPF which has long advocated on behalf of researchers and patients for accelerated research to treat and cure PF, both by the pharmaceutical industry and research funded by the National Institutes of Health (NIH). The CPF has also directly funded emerging research at several of the nation's leading centers for the treatment and study of PF including The University of Chicago, University of Michigan, and the David Geffen School of Medicine at UCLA and directed more than $400,000 in combined research funding since 2006 through its partnership with the American Thoracic Society (ATS). Complete details on CPF activities, including research, are available on our web page at: http://www.coalitionforpf.org/cpf_accomplishments.
'/>"/>

SOURCE Coalition for Pulmonary Fibrosis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
2. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
3. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
4. RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
5. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
8. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
11. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... WASHINGTON , Sept. 2, 2014 The ... America,s pharmacy benefit managers (PBMs), today filed a lawsuit ... a sweeping new Iowa law ... drug costs for the state,s employers and consumers.  ... generic drugs by severely restricting the use of Maximum ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
(Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... 1 study assessing the pharmacokinetics of a BEMA ... commercialize a high dose formulation of buprenorphine combined ... of opioid dependence. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ...
... -- Golden Meditech Holdings Limited ("Golden ... 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a ... cell cord blood banking operator in China, is pleased to ... With a track record in China for establishing ...
Cached Medicine Technology:BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 2BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 3BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 4Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 2Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 3
(Date:9/2/2014)... 2014 Today, Therapy Changes ... for Me?” The guide outlines common questions an individual ... addition to common types of groups an individual can ... from the interventions of the therapist, but also from ... group members,” says Rochelle Perper, Ph.D. and founder of ...
(Date:9/2/2014)... 02, 2014 The exciting information sessions ... professionals Carey Lewis and Bob Wiley. The ... those who have the desire to illuminate entertainment with ... performers could be invited to join the Bridge ... NC – Saturday, Sept. 6, Charlotte Convention Center, 501 ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... by helicopter, an expensive choice that may not impact patient ... and time is of the essence, helicopter transport is generally ... ground ambulance, but a paper published today in the online ... that the actual times to treatment for patients transported by ...
... HealthDay Reporter , WEDNESDAY, Oct. 12 (HealthDay ... for patients with a condition known as Barrett,s esophagus ... a large new Danish study suggests. Analyzing records ... determined that those with Barrett,s esophagus -- a disorder ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 12 ... marijuana run more than twice the risk of crashing compared to ... if the driver has also been drinking alcohol. The ... Reviews believe the findings are especially relevant in light of ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
... WEDNESDAY, Oct. 12 (HealthDay News) -- The death toll from ... risen to 23, and a total of 116 people have ... Control and Prevention reported late Wednesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
Cached Medicine News:Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Pot Smoking May More Than Double Crash Risk 2Health News:Pot Smoking May More Than Double Crash Risk 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2Health News:Death Toll From Cantaloupe-Linked Listeria Outbreak Now Stands at 23 2
... HCS INTERACTANT is ... system. Financial applications include ... human resources and comprehensive ... financial applications are designed ...
... is intended for the determination of C-Reactive ... on automated clinical chemistry analyzers. The erCRP ... a high sensitive method to ensure a ... entire measurable range (0.15 320mg/L). The ...
... Infinity Urea single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Urea reagent provides a long shelf ...
... The Infinity Lithium single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Lithium reagent provides a long ...
Medicine Products: